MarginsXMarginsX
Home › Markets › Health Care › VBIO

Valion Bio Inc. (VBIO)

VBIO trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5290
+0.84% on the day
Market cap
$1.1M
Nano cap
Revenue · 2024
$780K
-33.7% on 2023
Net income · 2024
-$5.7M
-725.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/0000950170-25-043234-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerVBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
CountryUnited States
IPO year2021
SEC CIK0001787740
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$780K
Net income-$5.7M
Operating income-$4.5M
Net margin-725.0%
Operating margin-573.8%
Revenue growth-33.7%
Cash$2.0M
Total assets$2.8M
P/E (computed)Net income was not positive
P/S (computed)1.5×

Warning signs

Cash runway
1.7 months
$2.1M cash at June 30, 2026
Share count, 1 year
+1948.9%
2025-08-12 to 2026-08-13 · +25631.5% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$28K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The aforementioned factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance date of the consolidated financial statements."
10-Q 2026-08-14
Cash and burn$2.1M cash; operating cash flow -$3.6M a quarter.Report 2026-06-30
Shares outstandingNo cover-page share count in XBRLCover page 2026-08-13
Reverse splits, 3 years2; latest 1-for-25 on 2026-08-31Source 2026-08-31
Shelf and offerings, 12 months4 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-16
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-03-20
AuditorRosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United StatesPCAOB Form AP 2026-04-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $28K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$7.1M-$5.3M$2.1M$7.4MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$6.2M-$5.0M$7.2M$6.9MNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$2.8M-$2.3M$12.6M$6.5MNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
$146K-$2.6M-$2.0M$3.5MNo debt tags$482K10-Q 2025-11-14
Q2 2025
2025-06-30
$86K-$1.9M-$1.8M$1.2MNo debt tags$462K10-Q 2025-08-14
Q1 2025
2025-03-31
$70K-$1.5M-$889K$669KNo debt tags$516K10-Q 2025-05-15
Q4 2024
2024-12-31
$180K-$1.5M-$1.4M$2.0M$0$780K10-K 2025-03-21
Q3 2024
2024-09-30
$126K-$1.4M-$1.4M$2.2MNo debt tags$957K10-Q 2024-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-21
Latest annual report
FORM 10-K
10-K2026-03-30
Latest quarterly / interim
FORM 10-Q
10-Q2026-08-14
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxy
DEFINITIVE PROXY STATEMENT
DEF 14A2026-10-16

Source: SEC EDGAR submissions feed, 407 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.7%
1 month-65.9%
3 months-87.6%
Year to date-98.5%
1 year-99.0%
From 52-week high-99.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus

TickerCompanyPriceDayMarket cap
NXLNexalin Technology Inc.$1.56+2.30%$1.9M
NUWENuwellis Inc.$4.48-8.57%$2.4M
NDRAENDRA Life Sciences Inc.$4.42-1.78%$6.6M
IRIXIRIDEX Corporation$0.6878-0.32%$12.1M
ITOCiTonic Holdings Ltd$1.88-5.05%$13.8M
QTIQT Imaging Holdings Inc.$1.80-4.26%$26.4M
ECORelectroCore Inc.$4.84-7.81%$44.7M
POCIPrecision Optics Corporation Inc.$4.97-4.97%$54.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier